Latest News and Press Releases

Addition is part of the annual reconstitution of the Nasdaq Biotech Index (NBI)Inclusion criteria include minimum market capitalization and daily trading volumes REYKJAVIK, Iceland, Dec. 23, 2024 ...

Alvotech verður hluti af NBI vísitölunni við opnun markaða í Bandaríkjunum 23. desember 2024  Alvotech (NASDAQ: ALVO) tilkynnti í dag að hlutabréf félagsins hafi verið tekin inn í Líftæknivísitölu...

Addition is part of the annual reconstitution of the Nasdaq Biotech Index (NBI)Inclusion criteria include minimum market capitalization and daily trading volumes Alvotech (NASDAQ: ALVO), a global...

Total Revenues in the first nine months of 2024 increased by $300 million compared to same period in 2023, to $339 million, with Q3 revenues contributing $103 millionProduct revenues in the first nine...

Heildartekjur á fyrstu níu mánuðum ársins jukust um 300 milljónir dala frá sama tímabili árið 2023, í 339 milljónir dala, þar af voru tekjur 103 milljónir dala á þriðja ársfjórðungi Tekjur af vörusölu...

Total Revenues in the first nine months of 2024 increased by $300 million compared to same period in 2023, to $339 million, with Q3 revenues contributing $103 millionProduct revenues in the first nine...

Alvotech (NASDAQ: ALVO) tekur þátt árlegum í heilbrigðisráðstefnum alþjóðlegu fjárfestingabankanna Citi og Evercore, dagana 4.-5. desember n.k. Auk þess að funda með fjárfestum munu stjórnendur...

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in Citi’s 2024...

REYKJAVIK, Iceland, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma, a UK headquartered global...